Effects of visceral adipose tissue on anti-tumour necrosis factor-α in Crohn’s disease
Background: It remains unclear whether visceral adipose tissue (VAT) can predict the response of patients with Crohn’s disease (CD) to anti-tumour necrosis factor-α (anti-TNF-α) therapy. Objectives: This study aimed to investigate whether VAT predicts the efficacy of infliximab (IFX) for different s...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-05-01
|
| Series: | Therapeutic Advances in Gastroenterology |
| Online Access: | https://doi.org/10.1177/17562848231171962 |
| _version_ | 1797832354473967616 |
|---|---|
| author | Kangrong Li Pan Gong Yongbin Zhang Minji Liu Zinan Zhang Xiaoyu Yu Mingmei Ye Li Tian |
| author_facet | Kangrong Li Pan Gong Yongbin Zhang Minji Liu Zinan Zhang Xiaoyu Yu Mingmei Ye Li Tian |
| author_sort | Kangrong Li |
| collection | DOAJ |
| description | Background: It remains unclear whether visceral adipose tissue (VAT) can predict the response of patients with Crohn’s disease (CD) to anti-tumour necrosis factor-α (anti-TNF-α) therapy. Objectives: This study aimed to investigate whether VAT predicts the efficacy of infliximab (IFX) for different sites of CD and its relationship with serum TNF-α levels and IFX serum trough concentration. Design: This is a multicentre retrospective study. Methods: Patients with CD treated with IFX from January 2014 to January 2021 were included. The perimeter of the visceral adipose area was obtained by a Computed Tomography (CT) scan. Participants were classified according to the lesion site (L 1 , L 2 , and L 3 ) and visceral fat area. The participants were divided into colon-uninvolved non-visceral obesity (L 1 -VAT L ), colon-uninvolved visceral obesity (L 1 -VAT H ), colon-involved non-visceral obesity (L 2 + L 3 -VAT L ), and colon involved visceral obesity (L 2 + L 3 -VAT H ) groups. The end points of this study were set as disease remission status at 6 and 12 months. Results: The final cohort included 140 patients. Regarding efficacy at 6 and 12 months, there was a significant difference between L 1 -VAT L (73.8% versus 36.8%, p = 0.006) and L 1 -VAT H (81.0% versus 47.4%, p = 0.008) groups. In the analysis of serum TNF-α levels and IFX serum trough concentrations, there was a significant difference between L 1 -VAT L and L 1 -VAT H (59.5 pg/mL versus 236.0 pg/mL, p TNF-α = 0.006), (10.0 μg/mL versus 0.4 μg/mL, p IFX = 0.000), and L 1 -VAT H and L 2 + L 3 -VAT H (78.7 pg/mL versus 118.6 pg/mL, p TNF-α = 0.031), (0.4 μg/mL versus 6.40 μg/mL, p IFX = 0.017). Conclusion: In L 1 patients, the VAT level predicted the efficacy of IFX, with high VAT values indicating poor efficacy. The VAT level may be a useful radiological marker to predict the efficacy of IFX in patients with various types of CD. |
| first_indexed | 2024-04-09T14:06:29Z |
| format | Article |
| id | doaj.art-51ff50bb6be147dabfdefd4535e21054 |
| institution | Directory Open Access Journal |
| issn | 1756-2848 |
| language | English |
| last_indexed | 2024-04-09T14:06:29Z |
| publishDate | 2023-05-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Gastroenterology |
| spelling | doaj.art-51ff50bb6be147dabfdefd4535e210542023-05-06T19:34:03ZengSAGE PublishingTherapeutic Advances in Gastroenterology1756-28482023-05-011610.1177/17562848231171962Effects of visceral adipose tissue on anti-tumour necrosis factor-α in Crohn’s diseaseKangrong LiPan GongYongbin ZhangMinji LiuZinan ZhangXiaoyu YuMingmei YeLi TianBackground: It remains unclear whether visceral adipose tissue (VAT) can predict the response of patients with Crohn’s disease (CD) to anti-tumour necrosis factor-α (anti-TNF-α) therapy. Objectives: This study aimed to investigate whether VAT predicts the efficacy of infliximab (IFX) for different sites of CD and its relationship with serum TNF-α levels and IFX serum trough concentration. Design: This is a multicentre retrospective study. Methods: Patients with CD treated with IFX from January 2014 to January 2021 were included. The perimeter of the visceral adipose area was obtained by a Computed Tomography (CT) scan. Participants were classified according to the lesion site (L 1 , L 2 , and L 3 ) and visceral fat area. The participants were divided into colon-uninvolved non-visceral obesity (L 1 -VAT L ), colon-uninvolved visceral obesity (L 1 -VAT H ), colon-involved non-visceral obesity (L 2 + L 3 -VAT L ), and colon involved visceral obesity (L 2 + L 3 -VAT H ) groups. The end points of this study were set as disease remission status at 6 and 12 months. Results: The final cohort included 140 patients. Regarding efficacy at 6 and 12 months, there was a significant difference between L 1 -VAT L (73.8% versus 36.8%, p = 0.006) and L 1 -VAT H (81.0% versus 47.4%, p = 0.008) groups. In the analysis of serum TNF-α levels and IFX serum trough concentrations, there was a significant difference between L 1 -VAT L and L 1 -VAT H (59.5 pg/mL versus 236.0 pg/mL, p TNF-α = 0.006), (10.0 μg/mL versus 0.4 μg/mL, p IFX = 0.000), and L 1 -VAT H and L 2 + L 3 -VAT H (78.7 pg/mL versus 118.6 pg/mL, p TNF-α = 0.031), (0.4 μg/mL versus 6.40 μg/mL, p IFX = 0.017). Conclusion: In L 1 patients, the VAT level predicted the efficacy of IFX, with high VAT values indicating poor efficacy. The VAT level may be a useful radiological marker to predict the efficacy of IFX in patients with various types of CD.https://doi.org/10.1177/17562848231171962 |
| spellingShingle | Kangrong Li Pan Gong Yongbin Zhang Minji Liu Zinan Zhang Xiaoyu Yu Mingmei Ye Li Tian Effects of visceral adipose tissue on anti-tumour necrosis factor-α in Crohn’s disease Therapeutic Advances in Gastroenterology |
| title | Effects of visceral adipose tissue on anti-tumour necrosis factor-α in Crohn’s disease |
| title_full | Effects of visceral adipose tissue on anti-tumour necrosis factor-α in Crohn’s disease |
| title_fullStr | Effects of visceral adipose tissue on anti-tumour necrosis factor-α in Crohn’s disease |
| title_full_unstemmed | Effects of visceral adipose tissue on anti-tumour necrosis factor-α in Crohn’s disease |
| title_short | Effects of visceral adipose tissue on anti-tumour necrosis factor-α in Crohn’s disease |
| title_sort | effects of visceral adipose tissue on anti tumour necrosis factor α in crohn s disease |
| url | https://doi.org/10.1177/17562848231171962 |
| work_keys_str_mv | AT kangrongli effectsofvisceraladiposetissueonantitumournecrosisfactoraincrohnsdisease AT pangong effectsofvisceraladiposetissueonantitumournecrosisfactoraincrohnsdisease AT yongbinzhang effectsofvisceraladiposetissueonantitumournecrosisfactoraincrohnsdisease AT minjiliu effectsofvisceraladiposetissueonantitumournecrosisfactoraincrohnsdisease AT zinanzhang effectsofvisceraladiposetissueonantitumournecrosisfactoraincrohnsdisease AT xiaoyuyu effectsofvisceraladiposetissueonantitumournecrosisfactoraincrohnsdisease AT mingmeiye effectsofvisceraladiposetissueonantitumournecrosisfactoraincrohnsdisease AT litian effectsofvisceraladiposetissueonantitumournecrosisfactoraincrohnsdisease |